{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:29:21Z","timestamp":1777922961869,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>\n                    New antimicrobial agents are being designed to treat infections of multidrug-resistant pathogens and have been introduced in the past few years, but there has been a worldwide increase in the incidence of vancomycin-resistant enterococci (VRE) infections, and treatment options are still limited. In this study, it was aimed to investigate the\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    activity of vancomycin combined with daptomycin against 30 VRE strains. The minimum inhibitory concentration (MIC) values of antibiotics were determined using broth microdilution assay as described by the Clinical and Laboratory Standards Institute (CLSI). The activities of antibiotics in combination were assessed using a broth microcheckerboard method. In addition, 4 of the 30 strains were randomly selected to determine the time-kill curves at 1\u2009\u00d7\u2009MIC concentrations and 2 of 4 strains at \u00bd\u2009\u00d7\u2009MIC concentrations. Viable counts were determined at 0-, 4-, 8-, 12-, 24-, 48-, and 72-hr intervals. This was accomplished by subculturing 0.1\u2009mL from repetitive serial dilutions in Eppendorf tubes, followed by subculturing 0.1\u2009mL from tubes onto Tryptic Soy Agar plates. All plates were incubated at 35\u00b0C for 24\u2009hr. The synergistic effect was found 100% using the broth microcheckerboard method, and in strains tested using the time-kill method at both 1\u2009\u00d7\u2009MIC and \u00bd\u2009\u00d7\u2009MIC concentrations. The results of this study suggest that this combination could be effective in the treatment of the VRE-associated infection.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2019.0033","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T10:59:41Z","timestamp":1564052381000},"page":"1484-1489","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["<i>In Vitro<\/i>\n                    Synergistic Effect of Vancomycin Combined with Daptomycin Against Vancomycin-Resistant Enterococci"],"prefix":"10.1177","volume":"25","author":[{"given":"Gulseren","family":"Aktas","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"Faron M.L. N.A. Ledeboer and B.W. Buchan. 2016. Resistance mechanisms epidemiology and approaches to screening for vancomycin-resistant Enterococcus in the health care setting. J. Clin. Microbiol. 54:2436\u20132447.","DOI":"10.1128\/JCM.00211-16"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"Hammerum A.M. S. Baig Y. Kamel L. Roer M. Pinholt H. Gumpert B. Holzknecht B. R\u00f8der U.S. Justesen J. Samulionien\u00e9 M. Kj\u00e6rsgaard C. \u00d8stergaard A. Holm E. Dzajic T.S. S\u00f8ndergaard S. Gaini P. Edquist E. Alm B. Lilje H. Westh M. Stegger and H. Hasman. 2017. Emergence of vanA Enterococcus faecium in Denmark 2005-15. J. Antimicrob. Chemother. 72:2184\u20132190.","DOI":"10.1093\/jac\/dkx138"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Kirst H.A. D.G. Thompson and T.I. Nicas. 1998. Historical yearly usage of vancomycin. Antimicrob. Agents Chemother. 42:1303\u20131304.","DOI":"10.1128\/AAC.42.5.1303"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"Van den Bunt G. J. Top J. Hordijk S.C. de Greeff L. Mughini-Gras J. Corander W. van Pelt M.J.M. Bonten A.C. Fluit and R.J.L. Willems. 2018. Intestinal carriage of ampicillin- and vancomycin-resistant Enterococcus faecium in humans dogs and cats in the Netherlands. J. Antimicrob. Chemother. 73:607\u2013614.","DOI":"10.1093\/jac\/dkx455"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Lebreton F. M.D. Valentino K. Schaufler A.M. Earl V. Cattoir and M.S. Gilmore. 2018. Transferable vancomycin resistance in clade B commensal-type Enterococcus faecium. J. Antimicrob. Chemother. 73:1479\u20131486.","DOI":"10.1093\/jac\/dky039"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"Guzman Prieto A.M. W. van Schaik M.R. Rogers T.M. Coque F. Baquero J. Corander and R.J. Willems. 2016. Global emergence and dissemination of enterococci as nosocomial pathogens: attack of the clones? Front Microbiol. 7:788.","DOI":"10.3389\/fmicb.2016.00788"},{"key":"e_1_3_3_8_2","unstructured":"Murray P.R. K.S. Rosenthal and M.A. Pfaller. 2016. Medical Microbiology. 8th ed. Elsevier Inc. Philadelphia."},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"Arias C.A. and B.E. Murray. 2012. The rise of the Enterococcus: beyond vancomycin resistance. Nat. Rev. Microbiol. 10:266\u2013278.","DOI":"10.1038\/nrmicro2761"},{"key":"e_1_3_3_10_2","unstructured":"Pillai S.K. Jr R.C. Moellering and G.M. Eliopoulos. 2005. Antimicrobial combinations. In V. Lorian (ed.) Antibiotics in laboratory medicine. Lippincott Williams and Wilkins Philadelphia pp. 365\u2013440."},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","unstructured":"O'Driscoll T. and C.W. Crank. 2015. Vancomycin-resistant enterococcal infections: epidemiology clinical manifestations and optimal management. Infect. Drug Resist. 8:217\u2013230.","DOI":"10.2147\/IDR.S54125"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Smith J.R. K.E. Barber A. Raut M. Aboutaleb G. Sakoulas and M.J. Rybak. 2015. \u03b2-lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J. Antimicrob. Chemother. 70:1738\u20131743.","DOI":"10.1093\/jac\/dkv007"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Hall Snyder A. B.J. Werth K.E. Barber G. Sakoulas and M.J. Rybak. 2014. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic\/pharmacodynamic simulated endocardial vegetation model. J. Antimicrob. Chemother. 69:2148\u20132154.","DOI":"10.1093\/jac\/dku113"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Entenza J.M. M. Giddey J. Vouillamoz and P. Moreillon. 2010. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin\/clavulanic acid or ampicillin. Int. J. Antimicrob. Agents 35:451\u2013456.","DOI":"10.1016\/j.ijantimicag.2009.12.022"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Sakoulas G. A.S. Bayer J. Pogliano B.T. Tsuji S.J. Yang N.N. Mishra V. Nizet M.R. Yeaman and P.A. Moise. 2012. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56:838\u2013844.","DOI":"10.1128\/AAC.05551-11"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Heidary M. A.D. Khosravi S. Khoshnood M.J. Nasiri S. Soleimani and M. Goudarzi. 2018. Daptomycin. J. Antimicrob. Chemother. 73:1\u201311.","DOI":"10.1093\/jac\/dkx349"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","unstructured":"Kelesidis T. R. Humphries D.Z. Uslan and D.A. Pegues. 2011. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin. Infect. Dis. 52:228\u2013234.","DOI":"10.1093\/cid\/ciq113"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","unstructured":"Taylor S.D. and M. Palmer. 2016. The action mechanism of daptomycin. Bioorg. Med. Chem. 24:6253\u20136268.","DOI":"10.1016\/j.bmc.2016.05.052"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","unstructured":"M\u00fcller A. M. Wenzel H. Strahl F. Grein T.N.V. Saaki B. Kohl T. Siersma J.E. Bandow H.G. Sahl T. Schneider and L.W. Hamoen. 2016. Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains. Proc. Natl. Acad. Sci. U. S. A. 113:E7077\u2013E7086.","DOI":"10.1073\/pnas.1611173113"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","unstructured":"Taylor R. K. Butt B. Scott T. Zhang J.K. Muraih E. Mintzer S. Taylor M. Palmer. 2016. Two successive calcium-dependent transitions mediate membrane binding and oligomerization of daptomycin and the related antimiotic A54145. Biochim. Biophys. Acta 1858:1999\u20132005.","DOI":"10.1016\/j.bbamem.2016.05.020"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","unstructured":"Hachmann A.B. E. Sevim A. Gaballa D.L. Popham H. Antelmann and J.D. Helmann. 2011. Reduction in membrane phospatidylglycerol content leads to daptomycin resistance in Bacillus subtilis. Antimicrob. Agents Chemother. 55:4326\u20134337.","DOI":"10.1128\/AAC.01819-10"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","unstructured":"Zhang T. J.K. Muraih B. MacCormick J. Silverman and M. Palmer. Daptomycin forms cation- and size-selective pores in model membranes. Biochim. Biophys. Acta 2014;1838: 2425\u20132430.","DOI":"10.1016\/j.bbamem.2014.05.014"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","unstructured":"Lee M.T. W.C. Hung M.H. Hsieh H. Chen Y.Y. Chang and H.W. Huang. 2017. Molecular state of the membrane-active antibiotic daptomycin. Biophys. J. 113:82\u201390.","DOI":"10.1016\/j.bpj.2017.05.025"},{"key":"e_1_3_3_24_2","unstructured":"Winn W. Jr. S. Allen W. Janda E. Koneman G. Procop P. Schreckenberger and G. Woods. 2006. Gram-positive cocci. In W. Winn Jr S. Allen W. Janda E. Koneman G. Procop P. Schreckenberger and G. Woods (ed.) Koneman's Color Atlas and Textbook of Diagnostic Microbiology. 6th ed. Lippincott Williams and Wilkins Philadelphia pp. 672\u2013764."},{"key":"e_1_3_3_25_2","doi-asserted-by":"crossref","unstructured":"Bryskier A. 2005. Antimicrobial Agents. ASM Press Washington DC.","DOI":"10.1128\/9781555815929"},{"key":"e_1_3_3_26_2","unstructured":"Clinical and Laboratory Standards Institute. 2015. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S25. CLSI Wayne PA."},{"key":"e_1_3_3_27_2","unstructured":"Clinical and Laboratory Standards Institute. 2006. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 7th ed. Approved Standard M7-A7. CLSI Wayne PA."},{"key":"e_1_3_3_28_2","unstructured":"Eliopoulos G.M. R.C. Moellering Jr and S.K. Pillai. 2005. Antimicrobial combinations. In V. Lorian (ed.) Antibiotics in laboratory medicine. Lippincott Williams and Wilkins Philadelphia pp. 365\u2013440."},{"key":"e_1_3_3_29_2","doi-asserted-by":"crossref","unstructured":"Odds F.C. 2003. Synergy antagonism and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.","DOI":"10.1093\/jac\/dkg301"},{"key":"e_1_3_3_30_2","unstructured":"Clinical and Laboratory Standards Institute. 1999. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. CLSI Wayne PA."},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","unstructured":"Bryskier A. and P. Veyssier. 2005. Glycopeptides and lipoglycopeptides. In A. Bryskier (ed.) Antimicrobial agents. ASM Press Washington DC pp. 880\u2013890.","DOI":"10.1128\/9781555815929.ch31"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2019.0033","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:35:01Z","timestamp":1777667701000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2019.0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1089\/mdr.2019.0033"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2019.0033","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}